Latest On-Demand Webinars & Online Events

Using the example of tumor-associated macrophages (TAMs), this webinar takes a closer look at immune cells in the tumor microenvironment (TME), helping us to gain a better understanding of how specific subtypes and their reprogramming may influence therapy efficiency.

We are thrilled to present an exclusive AMA featuring the distinguished Professor Mark Lawler, PhD, FRCPath.

Cancer cells engage in intricate interactions with neighboring cancerous and stromal cells through direct cell-to-cell contact and paracrine signaling. Long-range communication with distant organ sites is facilitated by extracellular vesicles, as well as signaling molecules like cytokines, hormones and growth factors .

In this webinar, you will learn about the OGM workflow and how it can be applied to cell and gene therapy R&D, with emphasis on how it can significantly improve the quality, safety and overall risk profile of next-generation therapies.

Antibodies are ideal therapeutic biomolecules due to their ability to bind to a variety of targets with high affinity and specificity. Innovations in hybridoma and phage display technologies have enabled drug developers to exploit the natural diversity in antibodies, leading to the wide use of monoclonal antibodies.

Natural killer (NK) cells are a promising tool in the fight against cancer. Engineering them with chimeric antigen receptors (CARs) further bolsters their specific anti-tumor activity.

This webinar describes how a new platform for high-throughput proteomics was used to identify multiple proteins associated with ovarian cancer. A 22-protein model was derived that discriminates ovarian cancer cases from benign controls with high accuracy.

This exclusive Ask Me Anything session delves into the cutting-edge advancements and international policy changes driving sustainability in the laboratory.

Transmembrane proteins (TPs) in their full-length and biologically active form presents challenges in purification primarily due to their innate complex structures. To overcome the challenges of expressing TPs, the FLAG technology from Acrobio addresses their protein expression knowledge to provide highly bioactive, stabilized, native full-length multi-pass transmembrane target antigens for the development of immune-related targeted therapeutics.

Liquid biopsies and the advent of blood-based diagnostics have emerged in recent years as promising alternatives and complements to tissue-based genomic and proteomic assays. Biodesix, a global leader in molecular diagnostics and assay design/development, leverages cutting-edge technology, including droplet digital PCR (ddPCR), to advance translational and clinical oncology research and to assist biopharma companies in delivering new, targeted, life-saving therapies to patients.

This presentation provides a comprehensive exploration of new blood-based diagnostics, including the development of a microsatellite instability (MSI) test on the ddPCR platform and the dynamic monitoring capabilities of ddPCR using circulating tumor DNA (ctDNA).